News
EVOK
--
0.00%
--
Evoke Pharma announces positive findings from second GIMOTI market research study
Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the
Seekingalpha · 06/15 13:07
BRIEF-Evoke Pharma And Eversana Announce Positive Findings From Second Gimoti® Market Research Study
reuters.com · 06/15 12:43
Evoke Pharma And EVERSANA Highlight Findings From Second GIMOTI Market Research Study
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science
Benzinga · 06/15 12:41
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI(R) Market Research Study
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA(TM), a leading provider of global commercial services to the life science industry, today announced positive findin...
GlobeNewswire · 06/15 12:30
Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Evoke Pharma (EVOK) jumps 8.4% premarket in reaction to the announcement that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's “Orange Book”.The patent covers methods
Seekingalpha · 06/08 13:04
Evoke Pharma Announces FDA Orange Book Listing Of US Patent For Gimoti
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti® (metoclopramide) nasal
Benzinga · 06/08 12:35
Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti(R)
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the U.S. Food and Dru...
GlobeNewswire · 06/08 12:30
Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti(R)
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed
GlobeNewswire · 06/02 13:27
BRIEF-Evoke Pharma Announces Issuance Of A New U.S. Patent Covering Methods Of Use For Gimoti
reuters.com · 06/02 13:25
Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical comp...
GlobeNewswire · 06/02 12:30
Evoke Pharma Wins US Patent on Methods of Use for Gimoti Nasal Spray
MT Newswires · 06/02 09:22
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti(R) Nasal Spray
Evoke is committed to meeting patients online, where they search for answers
GlobeNewswire · 05/27 12:30
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24)
Benzinga · 05/25 11:53
Evoke Pharma appoints Vickie Reed to board of directors
Evoke Pharma (EVOK) announces the appointment of Vickie Reed to the company’s board of directors.The appointment follows the retirement of Ann Rhoads from the company's board after a tenure of more than eight
Seekingalpha · 05/14 12:48
Evoke Pharma Appoints Vickie Reed to Board of Directors
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company's board of directors. After serving for more than eight years on t...
GlobeNewswire · 05/14 12:30
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
Benzinga · 05/14 09:19
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; ContextLogic Shares Plunge
Toward the end of trading Thursday, the Dow traded up 1.57% to 34,115.36 while the NASDAQ rose 0.78% to 13,133.31. The S&P also rose, gaining 1.43% to 4,121.09.
Benzinga · 05/13 18:36
Mid-Day Market Update: Crude Oil Down 3%; Flux Power Shares Rise After Q3 Results
Midway through trading Thursday, the Dow traded up 1.37% to 34,046.72 while the NASDAQ rose 1.08% to 13,173.00. The S&P also rose, gaining 1.29% to 4,115.26.
Benzinga · 05/13 16:14
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc.
Benzinga · 05/13 16:05
Webull provides a variety of real-time EVOK stock news. You can receive the latest news about Evoke Pharma through multiple platforms. This information may help you make smarter investment decisions.
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.